BioMarin Provides Update on FDA Review of ROCTAVIAN™ (Valoctocogene Roxaparvovec) Gene Therapy for Adults with Severe Hemophilia A ...Middle East

FDA Extends PDUFA Target Action Date to June 30, 2023 SAN RAFAEL, Calif., March 6, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today announced that it received notice this...

Hence then, the article about biomarin provides update on fda review of roctavian valoctocogene roxaparvovec gene therapy for adults with severe hemophilia a was published today ( Tuesday 07/03/2023 - 03:36 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( BioMarin Provides Update on FDA Review of ROCTAVIAN™ (Valoctocogene Roxaparvovec) Gene Therapy for Adults with Severe Hemophilia A )

Also on site :

• Russia-Ukraine war: List of key events, day 1,426
• Rangers’ Cody Bradford Targeting Return In May From Elbow Surgery
• '90s Trash Metal Band Releases New Single Ahead of Farewell Album